Uterine leiomyosarcomas

References

• Brooks SE, Zhan M, Cote T, Baguet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93: 204–208.
   PubMed Web of Science ®Google Scholar
• Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414.
   Google Scholar
• Chander S, Lay Ergun E. Positron emission tomographic-computed tomographic imaging of uterine sarcoma. Clin Nucl Med 2003;28:443–444.
   PubMedGoogle Scholar
• Cantisani V, Mortele KJ, Kalantari BN, et al. Vaginal metastasis from uterine leiomyosarcoma. Magnetic reso-nance imaging features with pathological correlation. J Comput Assist Tomogr 2003;27:805–809.
   Google Scholar
• Kurma RJ. Pathology of the Female Genital Tract. 4th ed, Springer-Verlang, New York, p. 499.
   Google Scholar
• Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18: 535.
   Google Scholar
• Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retro-spective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy small star, filled. Gynecol Oncol 2003;89:460.
   PubMed Web of Science ®Google Scholar
• Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors. A study of 27 cases. Arch Pathol Lab Med 2000;124: 1471–1475.
   Google Scholar
• Raspollini MR, Amunni G, Villanucci A, Pinzani P, Simi L, et al. c-Kit expression in patients with uterine leiomyo-sarcomas: a potential alternative therapeutic treatment. Clinical Cancer Research 2004;10:3500–3503.
   PubMed Web of Science ®Google Scholar
• Leiser A, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Soslow RA. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 2006;101:86–91.
   Google Scholar
• Bodner-Alder B, Bodner K, Kimberger O, et al. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters. J Soc Gynecol Investig 2003;10: 443–446.
   Google Scholar
• Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer 2003;98:1029–1038.
   PubMed Web of Science ®Google Scholar
• Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702.
   Google Scholar
• Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003;91:209.
   PubMed Web of Science ®Google Scholar
• Reed NS, Mangioni C, Malmstrom H, et al. First results of a randomized trial comparing radiotherapy versus ob-servation postoperatively in patients with uterine sarco-mas. An EORTC-GCG Study (abstract). Int J Gynecol Cancer 2003;13\(suppl 1);4.
   Google Scholar
• Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L, Arisio R, Romagnolo C, Cristofani R. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25–32.
   PubMed Web of Science ®Google Scholar
• Homback NB, Omura G, Major FJ. Observations of the use of adjuvant radiation therapy in patients with stage I and II uterine sarcomas. Int J Radiat Oncol Biol Phys. 1986;12:2127–2130.
   Google Scholar
• Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 3:1240.
   PubMed Web of Science ®Google Scholar
• Hensley ML. Uterine sarcomas and carcinosarcomas: Advances for adjuvant disease and updates on adjuvant therapy. ASCO 2006;301–304.
   Google Scholar
• Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 2002;87:287.
   PubMed Web of Science ®Google Scholar
• Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992;45:202.
   PubMed Web of Science ®Google Scholar
• Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazeno-imidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626.
   PubMed Web of Science ®Google Scholar
• Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclopho-sphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648.
   Google Scholar
• Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005;97:624.
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing J, Hanjani P, Kramer P. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:749.
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556.
   PubMed Web of Science ®Google Scholar
• Slayton R, Blessing JA, Barrett FJ, et al. Phase II trial of etoposide in the management of advanced or recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group Study. Cancer Treat Rep 1987;71:1303.
   PubMedGoogle Scholar
• Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2004;92:644–647.
   PubMed Web of Science ®Google Scholar
• Currie JL, Blessing JA, Muss HB, et al. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyo-sarcoma: A Gynecologic Oncology Group Study. Gynecol Oncol 1996;61:27–30.
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1996;62: 226.
   Google Scholar
• >ThigpcnJT, Blessing ]A, Bcccham J, ctal. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent sarcomas: A Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962–1966.
   Google Scholar
• Rose PG, Blessing JA, Sper JT, et al. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1998;70:267–271.
   PubMed Web of Science ®Google Scholar
• Slayton R, Blessing JA, Look K, et al. A phase II trial of diazoquonc (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Invest New Drugs 1991;9:207.
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing J A, Kilgorc LC, et al. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: A Gynecologic Oncology Group study. Am J Clin Oncol 2OO0;23(4):355–357.
   Google Scholar
• Gallup DG, Blessing JA, Anderson W, et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 2003;89:48–51.
   Google Scholar
• Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: A Gynecologic Oncol-ogy Group study. Gynecol Oncol 1999;74:346–349.
   Google Scholar
• McMeekin DS, Sill M, Benbrook D. A phase II study of thalidomide in patients with recurrent or persistent leiomyosarcoma (LMS) of the uterus: A Gynecologic Oncology Group study. Proc Soc Gynecol Oncol 2004 (abstr 104).
   Google Scholar
• Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2002;84:140–144.
   Google Scholar
• Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyo-sarcoma: Results of a Phase II Trial. J Clin Oncol 2002;20:2824.
   PubMed Web of Science ®Google Scholar
• Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol 2005;6:961–971.
   PubMed Web of Science ®Google Scholar
• Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 2004;16:261.
   Google Scholar
• Dinh TA, Oliva EA, Fuller AF Jr, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experi-ence (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004;92:648.
   Google Scholar
• Bodner K, Bodner-Adler B, Kimberger O, et al. Evaluat-ing prognostic parameters in women with uterine leiomyosarcoma. A clinicopatholgic study. J Reprod Med 2003;48:95–100.
   PubMed Web of Science ®Google Scholar